Drug-eluting stents in preclinical studies: updated consensus recommendations for preclinical evaluation.
about
The representative porcine model for human cardiovascular diseaseEffects of an alpha-4 integrin inhibitor on restenosis in a new porcine model combining endothelial denudation and stent placementThreats to validity in the design and conduct of preclinical efficacy studies: a systematic review of guidelines for in vivo animal experimentsReducing Neointima Formation in a Swine Model with IVUS and Sirolimus Microbubbles.Preclinical study of a biodegradable polymer-based stent with abluminal sirolimus release.Effect of a dual drug-coated stent with abciximab and alpha-lipoic Acid in a porcine coronary restenosis model.Quantitative analysis of high-resolution, contrast-enhanced, cone-beam CT for the detection of intracranial in-stent hyperplasia.Dynamic observation of artery endothelial cell layers in response to bare metal stent and paclitaxel-eluting stent in vitro.Targeted disruption of LDLR causes hypercholesterolemia and atherosclerosis in Yucatan miniature pigsA new polymer-free drug-eluting stent with nanocarriers eluting sirolimus from stent-plus-balloon compared with bare-metal stent and with biolimus A9 eluting stent in porcine coronary arteriesComparative vascular responses three months after paclitaxel and everolimus-eluting stent implantation in streptozotocin-induced diabetic porcine coronary arteries.Modelling the Impact of Atherosclerosis on Drug Release and Distribution from Coronary StentsModels for preclinical studies in aging-related disorders: One is not for all.Mechanical and Histopathological Comparison between Commercialized and Newly Designed Coronary Bare Metal Stents in a Porcine Coronary Restenosis Model.Biological effect on drug distribution and vascular healing via paclitaxel-coated balloon technology in drug eluting stent restenosis swine model.Histopathological Comparison among Biolimus, Zotarolimus and Everolimus-Eluting Stents in Porcine Coronary Restenosis Model.Mucin covalently bonded to microfibers improves the patency of vascular grafts.Effect of atorvastatin-eluting stents in a rabbit iliac artery restenosis model.Adventitial nab-rapamycin injection reduces porcine femoral artery luminal stenosis induced by balloon angioplasty via inhibition of medial proliferation and adventitial inflammation.Long-term effect of stents eluting 6-mercaptopurine in porcine coronary arteries.Effect of Stents Coated with Artemisinin or Dihydroartemisinin in a Porcine Coronary Restenosis Model.The Control of Drug Release and Vascular Endothelialization after Hyaluronic Acid-Coated Paclitaxel Multi-Layer Coating Stent Implantation in Porcine Coronary Restenosis Model.Preclinical models of restenosis and their application in the evaluation of drug-eluting stent systems.A novel PDGF receptor inhibitor-eluting stent attenuates in-stent neointima formation in a rabbit carotid model.Role of Animal Models in Coronary Stenting.Miniature Swine for Preclinical Modeling of Complexities of Human Disease for Translational Scientific Discovery and Accelerated Development of Therapies and Medical Devices.Paving the way to a bioresorbable technology: Development of the absorb BRS program.Historical Incidence of Spontaneous Lesions in Kidneys from Naïve Swine Utilized In Interventional Renal Denervation Studies.Effect of stents coated with a combination of sirolimus and alpha-lipoic acid in a porcine coronary restenosis model.The SYNERGY biodegradable polymer everolimus eluting coronary stent: Porcine vascular compatibility and polymer safety study.Lesion complexity determines arterial drug distribution after local drug delivery.Serial changes of neointimal tissue after everolimus-eluting stent implantation in porcine coronary artery: an optical coherence tomography analysis.Vascular Response to Experimental Stent Malapposition and Under-Expansion.A histopathological comparison of different definitions for quantifying in-stent neointimal tissue: implications for the validity of intracoronary ultrasound and optical coherence tomography measurements.Familial hypercholesterolemia and atherosclerosis in cloned minipigs created by DNA transposition of a human PCSK9 gain-of-function mutant.Experimental evaluation of pharmacokinetic profile and biological effect of a novel paclitaxel microcrystalline balloon coating in the iliofemoral territory of swine.Sex differences in the outcomes of stent implantation in mini-swine model.Bilirubin coating attenuates the inflammatory response to everolimus-coated stents.The use of an occlusion perfusion catheter to deliver paclitaxel to the arterial wall.Defining drug and target protein distributions after stent-based drug release: Durable versus deployable coatings.
P2860
Q27692622-9B7A7931-8C19-4DDB-A542-45AE61532824Q28476506-FE5A8C0D-442C-4430-AE4E-6FC1C62E4DEFQ28534767-84ED75FE-1833-4669-96D8-8D4691CA5235Q30300162-4032AADF-DB66-463E-8666-4E8461D1A535Q33733393-07C3010D-ADFB-4FA3-9BD2-72FF3E75FDE7Q35048369-A66B3AE5-6F11-46BF-ABFE-DC9632DB66FDQ35048552-D5D84D5E-A1CC-44C1-9735-88C609767D29Q35085453-A980819E-92CA-4E6F-9BC6-F1E453FA79DCQ35137644-785BF137-F341-4CCE-ABE0-AEE34DADBD2EQ35572141-18F00299-1533-4C76-A936-8AEF3257FA1EQ36146253-BDBA98A3-8F4B-4014-8BDD-76556F90A250Q36610213-13D4368F-ED5B-4BA8-A4D7-BA67D8A74982Q36738466-4F1A408F-AA8C-4F0C-8EEC-699D3C340983Q36837612-9C25F296-7CD4-4B9D-9964-0686D4AA2CF5Q37337286-06AE2A17-60AC-4F6E-9412-E5C9B363FA36Q37399625-ACF0A50B-5D09-4916-B30A-559CB76DE659Q37419171-C6C29B61-DF49-459B-96DF-02612D468872Q37435145-A75F1FFE-C0E1-469F-A370-E83171E561F9Q37463102-B10E13EE-4AC4-440A-BB59-E116F6292D64Q37472459-EC00F20E-3DCA-4587-8BB6-E5E6A889ED7BQ37619057-AC62E7BF-1792-465C-8673-875BFA0FAF2DQ37619061-58545726-24A8-4485-817F-61CBB655B382Q37676695-F273F315-6A14-414D-BAD6-3BFDF99C172DQ37707729-BC1D2381-E0FD-405B-BCB2-B7B8184D3A5FQ38563916-01AFD0A2-1243-4D03-A93D-8308088DD352Q38721240-FD33EA1B-67BE-4774-A4BC-C20403AAEA99Q38995000-BF77347D-2B5B-4A1A-862B-2DF6ADBC7F15Q39759256-15E13406-3AAE-450C-A1F8-37EEB0FF8CB9Q39990421-6B1BF162-E99A-4BA8-A1D3-3B388CEE082EQ40903334-ABD137EF-9C7F-41CD-94A3-6D83A3ABF9F5Q41415263-DB70E782-DCC4-469D-8E8F-5CE8F2CEC0E7Q41981596-77F8DC1F-861E-470C-A016-F8881541B57DQ42574579-AE1A237F-9506-4945-BDC9-B9C594B7AA12Q42870553-D3CA0DE1-237F-4CE8-A0A1-6353918ECCFEQ44937777-96291F03-5F6F-444D-AD0C-590A1D121E40Q45789357-3DC7327F-650C-421C-8613-5A3E822C820AQ47548427-0AE327E0-C647-43C8-9077-B7B0A4B11FA1Q47943695-16973F19-3DD8-4CC3-91CE-1394B9CB35F1Q48228974-EEDA9475-B4A9-4FB7-94D2-ECF68BEF06D6Q50053068-8E009464-8AF9-455B-806B-8A8EE8A85D3B
P2860
Drug-eluting stents in preclinical studies: updated consensus recommendations for preclinical evaluation.
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Drug-eluting stents in preclin ...... ns for preclinical evaluation.
@ast
Drug-eluting stents in preclin ...... ns for preclinical evaluation.
@en
Drug-eluting stents in preclin ...... ns for preclinical evaluation.
@nl
type
label
Drug-eluting stents in preclin ...... ns for preclinical evaluation.
@ast
Drug-eluting stents in preclin ...... ns for preclinical evaluation.
@en
Drug-eluting stents in preclin ...... ns for preclinical evaluation.
@nl
prefLabel
Drug-eluting stents in preclin ...... ns for preclinical evaluation.
@ast
Drug-eluting stents in preclin ...... ns for preclinical evaluation.
@en
Drug-eluting stents in preclin ...... ns for preclinical evaluation.
@nl
P2093
P2860
P1476
Drug-eluting stents in preclin ...... ns for preclinical evaluation.
@en
P2093
Andrew Carter
Elazer Edelman
Greg L Kaluza
Gregory J Wilson
Juan F Granada
Judah Weinberger
Keith A Robinson
Nicolas A F Chronos
Renu Virmani
Robert L Wilensky
P2860
P304
P356
10.1161/CIRCINTERVENTIONS.108.789974
P577
2008-10-01T00:00:00Z